Avidity Biosciences Current Ratio 2019-2022 | RNA
Avidity Biosciences current ratio from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Avidity Biosciences Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-03-31 |
$0.41B |
$0.03B |
13.09 |
| 2021-12-31 |
$0.41B |
$0.03B |
13.86 |
| 2021-09-30 |
$0.42B |
$0.02B |
18.82 |
| 2021-06-30 |
$0.29B |
$0.02B |
17.59 |
| 2021-03-31 |
$0.31B |
$0.02B |
17.81 |
| 2020-12-31 |
$0.33B |
$0.02B |
22.74 |
| 2020-09-30 |
$0.34B |
$0.01B |
25.17 |
| 2020-06-30 |
$0.35B |
$0.01B |
30.45 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2019-06-30 |
$0.00B |
|
0.00 |
| 2018-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.644B |
$0.009B |
|
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
|
